|
Funding Agency: AIM AHEAD Title: Multiple Calls for Proposals Application Deadline: June 2023 (Solicitation release: April 2023) The National Institutes of Health’s Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD) program has established mutually beneficial, coordinated, and trusted partnerships to enhance the participation and representation of researchers and communities currently underrepresented in the development of AI/ML models and to improve the capabilities of this emerging technology, beginning with electronic health records (EHR) and extending to other diverse data to address health disparities and inequities. UH is a member of AIM AHEAD. Funding Agency: National Institutes of Health Title: BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Application Deadline: June 07, 2023 Reissue of RFA-MH-22-220 to comply with DMSP. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope. Funding Agency: National Institutes of Health Title: Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) Application Deadline: June 23, 2023 and June 21, 2024 The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels. Funding Agency: National Institutes of Health Title: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) Application Deadline: Multiple deadlines This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This NOFO is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and studies that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-23-157. Funding Agency: National Institutes of Health Title: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Application Deadline: Multiple deadlines This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282 Funding Agency: National Institutes of Health Title: Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) Application Deadline: Multiple deadlines This Notice of Funding Funding Opportunity (NOFO) supports research on expectancy-generating factors and measures of their effects on expectancies and subsequent cancer symptom management outcomes; and research to identify moderators of such expectancy effects. Specifically, this NOFO will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including ones response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research. Funding Agency: National Institutes of Health Title: Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) Application Deadline: September 25, 2023 Reissue of PAR-21-112 to add renewal as an application type in Sections II and V. The specific purpose of this NOFO is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD. Funding Agency: National Institutes of Health Title: Development and Validation of Models for Alzheimer’s Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Application Deadline: October 20, 2023 "This FOA would support development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Either way, it is essential that models reflect the human condition as much as possible. Novel models of complex pathology or comorbid conditions are encouraged. Such models could include multiple manipulations (genetics, environment, lifestyle, age, etc.) to better reflect the complex interaction of risk factors in patients. New models need to be innovative and address a gap in the currently available models." Funding Agency: National Institutes of Health Title: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Application Deadline: Multiple deadlines This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of, pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Funding Agency: National Institutes of Health Title: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) Application Deadline: Multiple deadlines This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Funding Agency: National Institutes of Health Title: Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed) Application Deadline: August 25, 2023 The purpose of this Funding Opportunity Announcement (FOA) is to promote basic research to better understand the mechanisms underlying viral invasion of the central nervous system (CNS), virus- and/or host immune-mediated neuropathogenesis, and the associated clinical manifestations for emerging and re-emerging neurotropic viruses. Funding Agency: National Institutes of Health Title: Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed) Application Deadline: October10, 2023 This RFA aims to support the development, testing, validation and implementation of quality metrics in mental health services research, that can be submitted to and endorsed by the relevant regulatory or governing bodies. In order to support the implementation and dissemination of high-quality mental health services, effective measures of defining and assessing quality are needed. Very few measures exist for assessing the quality of mental health care services; as noted by the Agency for Healthcare Research and Quality (AHRQ), these measures are not typically standardized or utilized uniformly. These quality measures can be used by policymakers, payers, organizational leaders, and clinicians for a variety of endeavors, including providing measurement-based care, evaluating the effectiveness of evidence-based care, enacting quality improvement interventions, assessing comparative- and cost-effectiveness across programs or clinical settings, utilizing real-world data in decision-making, and developing payment models, in order to continually improve mental health functioning and outcomes. Funding Agency: Center for Disease Control and Prevention Title: Essentials for Childhood (EfC): Preventing Adverse Childhood Experiences through Data to Action Application Deadline: June 12, 2023 Essentials for Childhood (EfC): Preventing Adversity through Data to Action, a cooperative agreement designed to support states in the prevention of adverse childhood experiences (ACEs) and promotion of positive childhood experiences (PCEs). ACEs are preventable, potentially traumatic events that occur in childhood (0-17 years) such as experiencing or witnessing violence, experiencing neglect; witnessing violence in the home. Also included are aspects of the child’s environment that can undermine their sense of safety, stability, and bonding such as growing up in a household with substance use problems, mental health problems, or instability due to parental separation or incarceration of a parent, sibling or other member of the household. ACEs can have significant consequences, including associations with poor health outcomes (e.g., asthma, cancer, heart disease), health risk behaviors (e.g., current smoking and heavy drinking), mental health challenges (depression, anxiety), and socioeconomic challenges (e.g., unemployment and no health insurance). Funding Agency: Health Resources and Services Administration Title: Maternal Health Research Collaborative for Minority-Serving Institutions (MH-RC-MSI) Research Centers (RCs) Application Deadline: June 12, 2023 This notice announces the opportunity to apply for funding under HRSA-23-112: Maternal Health Research Collaborative for Minority-Serving Institutions (MH-RC-MSI) Research Centers (RCs) and HRSA-23-113: MH-RC-MSI Coordinating Center (CC).The purpose of the Maternal Health Research Collaborative for Minority-Serving Institutions (MSIs)3 [hereafter referred to as the Collaborative] is to establish a multi-institutional research network that is comprised of and supports minority-serving institutions (MSIs) to build their capacity to conduct research addressing disparities in maternal mortality, severe maternal morbidity, and maternal health outcomes and to find community-based solutions to address these disparities and advance health equity. Funding Agency: Health Resources and Services Administration Title: Maternal Health Research Collaborative for Minority-Serving Institutions (MH-RC-MSI) Coordinating Center (CC) Application Deadline: June 12, 2023 This notice announces the opportunity to apply for funding under HRSA-23-112: Maternal Health Research Collaborative for Minority-Serving Institutions (MH-RC-MSI) Research Centers (RCs) and HRSA-23-113: MH-RC-MSI Coordinating Center (CC).The purpose of the Maternal Health Research Collaborative for Minority-Serving Institutions (MSIs)3 [hereafter referred to as the Collaborative] is to establish a multi-institutional research network that is comprised of and supports minority-serving institutions (MSIs) to build their capacity to conduct research addressing disparities in maternal mortality, severe maternal morbidity, and maternal health outcomes and to find community-based solutions to address these disparities and advance health equity. Funding Agency: Health Resources and Services Administration Title: State Maternal Health Innovation Program Application Deadline: June 02, 2023 This notice announces the opportunity to apply for funding under the FY 2023 State Maternal Health Innovation (State MHI) program. The purpose of this program is to reduce maternal mortality and severe maternal morbidity (SMM) 1 by supporting state-led demonstrations focused on improving maternal health and addressing maternal health disparities through quality services, a skilled workforce, enhanced data quality and capacity, and innovative programming. This program also engages public health professionals, providers, payers, and consumers through state-led Maternal Health Task Forces (MHTF). These Task Forces review state-specific maternal health data and then implement evidence-based interventions and innovations that address critical gaps. FY 2023 funding for this program seeks to provide support to expand to new states focused on improving maternal health. Potential applicants should design submissions to implement innovations to improve health outcomes, develop state-specific plans that will guide maternal health efforts, and enhance measurement of maternal health outcomes. Funding Agency: Department of Health and Human Services Title: PATC³H-IN Implementation Science Coordinating Center (UM2 Clinical Trial Optional) Estimated Application Deadline: December 06, 2023 The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with other NIH Institutes and Centers (ICs) including the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Fogarty International Center (FIC), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H-IN). The Network will expand and/or improve successes achieved by PATC3H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more. Funding Agency: Department of Health and Human Services Title: Advancing Genomic Medicine Research (R01 Clinical Trial Optional) Estimated Application Deadline: October 06, 2023 The National Human Genome Research Institute intends to issue a Notice of Funding Opportunity (NOFO) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups. Funding Agency: Department of Health and Human Services Title: Food is Medicine Research Opportunities RFI Deadline: June 30, 2023 This Request for Information (RFI) invites input on research opportunities and best practices for Food is Medicine research programs. These programs are part of a whole-of-government approach to end hunger, improve nutrition and physical activity, and reduce diet-related diseases and disparities. Review of this entire RFI notice is encouraged to ensure a comprehensive response is prepared and to have a full understanding of how your response will be used.
|
